Stock Yearly Return 2022
Start date: 01/03/2022
End date: 12/30/2022
Start price/share: $3.64
End price/share: $6.27
Dividends collected/share: $0.00
Total return: 72.25%
CBAY Average Annual Return: 73.05%
Starting investment: $10,000.00
Ending investment: $17,225.00
Years: 0.99


CBAY average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare CBAY average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into CBAY


Also see:
CBAY YTD return
CBAY average annual return 10 years
CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases. Co.'s pipeline includes the following clinical stage product candidates: seladelpar, a selective agonist for the peroxisome proliferator-activated receptor delta, which is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells; and MBX-2982, which targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. The CBAY stock yearly return is shown above.

The yearly return on the CBAY stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2022 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the CBAY annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree CBAY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
CymaBay Therapeutics (CBAY) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

CBIO Average Annual Return
CCCC Average Annual Return
CCEL Average Annual Return
CCRN Average Annual Return
CDAK Average Annual Return
CDMO Average Annual Return
CDNA Average Annual Return
CDRE Average Annual Return
CDTX Average Annual Return
CDXC Average Annual Return
More Healthcare companies »

 

CBAY Stock Yearly Return 2022 | www.AverageAnnualReturn.com | Copyright © 2021 - 2023, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.